Şunu aradınız:: komplementaktiveringen (Danca - İngilizce)

eculizumab bevarer de tidlige komponenter af komplementaktiveringen, der er essentiel for opsonisering af mikroorganismer og elimination af immunkomplekser.
eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes.

der er ikke rapporteret klinisk relevant komplementaktivering i kliniske forsøg, men der er under bivirkningsovervågningen efter markedsføring rapporteret om anafylaktiske reaktioner.
no clinically relevant complement activation was reported in clinical trials but anaphylactic reactions have been reported during post-marketing surveillance.